Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VX-880
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : $780.0 million
Deal Type : Licensing Agreement
Vertex and TreeFrog Therapeutics Announce Licensing Agreement for Cell Therapies
Details : Under the agreement, Vertex licenses TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of its cell therapies, including VX-880, for type 1 diabetes (T1D).
Brand Name : VX-880
Molecule Type : Cell and Gene therapy
Upfront Cash : $25.0 million
April 23, 2024
Lead Product(s) : VX-880
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : $780.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
